Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Phase 2 | terminated | Feb 21, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant… | Phase 1 | terminated | May 11, 2022 | Lava Therapeutics | The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2). | Other (stated, no rule matched) |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural… | Phase 2 | terminated | Aug 23, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT06264479 | Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal…(PEAR-TREE2) | — | terminated | Feb 20, 2024 | Ourotech, Inc. | Lack of funding | Funding |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | Phase 3 | terminated | Jun 21, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04832997 | Micro-ultrasound for Prostate Cancer Diagnosis | N/A | terminated | Apr 6, 2021 | IRCCS San Raffaele | The study faced structural and methodological obstacles, with limited enrollment, technical issues,… | Enrollment / accrual |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT06655064 | Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT… | — | terminated | Oct 23, 2024 | Telix Pharmaceuticals (Innovations) Pty Limited | Sponsor request | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant…(TALON) | Phase 2 | withdrawn | Sep 29, 2020 | Duke University | Discontinuation of funding | Funding |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With… | — | withdrawn | Dec 30, 2020 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT05333432 | Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of…(HRPCa-II) | N/A | withdrawn | Apr 19, 2022 | Assistance Publique - Hôpitaux de Paris | difficulties in setting up the study within the investigation centers in connection with complex… | Other (stated, no rule matched) |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT01231932 | Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and… | — | terminated | Nov 1, 2010 | National Institute of Nursing Research (NINR) | Principal Investigator (PI) of this study is retiring. | Investigator |
| NCT04503668 | Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic… | Phase 3 | terminated | Aug 7, 2020 | University of Michigan Rogel Cancer Center | Lack of Patient Population | Other (stated, no rule matched) |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Phase 1 / Phase 2 | withdrawn | Jan 18, 2023 | VA Office of Research and Development | The study drug is not available. | Other (stated, no rule matched) |
| NCT05029154 | Exercise Preconditioning in Ovarian Cancer | N/A | terminated | Aug 31, 2021 | University of Virginia | Accrual not meeting pre-specified numbers. | Enrollment / accrual |
| NCT05712174 | A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | Phase 2 | terminated | Feb 3, 2023 | AHS Cancer Control Alberta | Accrual to the biochemically recurrent and metastatic cohorts complete; however, accrual to the… | Enrollment / accrual |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent… | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | Phase 1 / Phase 2 | terminated | Oct 19, 2018 | Medical University of South Carolina | Interim study results were not favorable to continue with further enrollment. | Enrollment / accrual |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic…(ADAPTeR) | Phase 2 | terminated | May 18, 2015 | Royal Marsden NHS Foundation Trust | The study was unable to recruit the target number of patients (enrolled 15 instead of 19) and did… | Enrollment / accrual |
| NCT06421311 | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With…(URADJ) | — | terminated | May 20, 2024 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Phase 1 | terminated | Sep 27, 2017 | Dana-Farber Cancer Institute | Safety Implications | Safety / toxicity |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | Phase 3 | withdrawn | May 18, 2015 | National Institute of Cancerología | Due to a lack of sufficient resources, the opening was not carried out. | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT01673984 | GP Extended Action Triptorelin(GREAT) | Phase 4 | terminated | Aug 28, 2012 | Ipsen | The study was discontinued prematurely by the sponsor due to non-medical reasons | Other (stated, no rule matched) |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant… | Phase 1 / Phase 2 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | Abandoned | Other (stated, no rule matched) |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT03255252 | Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer…(IMMUVIX) | Phase 2 | terminated | Aug 21, 2017 | Institut du Cancer de Montpellier - Val d'Aurelle | insufficient recruitment | Enrollment / accrual |
| NCT00635167 | Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity… | N/A | terminated | Mar 13, 2008 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Closed by PI final report submitted | Other (stated, no rule matched) |
| NCT04926181 | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine… | Phase 2 | terminated | Jun 15, 2021 | Rahul Aggarwal | Funding | Funding |
| NCT05396794 | Bariatric Education for Women With Obesity and Endometrial Cancer(SCC-BAREDU) | — | terminated | May 31, 2022 | University of Oklahoma | No Surgeon to perform the operations. | Other (stated, no rule matched) |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Oct 3, 2017 | University of Michigan Rogel Cancer Center | Cancelled by the sponsor | Other (stated, no rule matched) |
| NCT03456700 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | Phase 2 | terminated | Mar 7, 2018 | Mayo Clinic | The study is closed per results from the interim analysis. | Efficacy / futility |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 3, 2025source: clinicaltrials